Advisory Board September 8, 2025

FDA is requiring patients taking the Alzheimer’s drug Leqembi to undergo additional monitoring after routine pharmacovigilance identified six deaths early in the treatment, in today’s bite-sized hospital and health industry news from Illinois, Maryland, and Texas.

  • Illinois: Last month, the American Hospital Association (AHA) elected nine new members to its board of trustees. The members will serve three-year terms effective Jan. 1, 2026. Incoming members of AHA’s board include: Debra Albert, CNO and SVP for patient care services at NYU Langone Health; Rob Allen, president and CEO of Intermountain Health; J.P. Gallagher, president and CEO of Endeavor Health; Leah Glasgo, president of UnityPoint Health; Melinda Hancock, EVP and CFO of Sentara Health; Michael Slubowski, president and CEO of...

Today's Sponsors

Venturous
ZeOmega

Today's Sponsor

Venturous

Continue Reading

 
Topics: Biotechnology, FDA, Govt Agencies, Patient / Consumer, Pharma, Pharma / Biotech, Provider
Related Articles:
FDA guidance eases wearables oversight. But experts have questions about what’s next.
AI Model FDA-Cleared to Triage 14 Conditions
The Promise And Perils Of FDA’s New ‘Plausible Mechanism’ Pathway (Part 2)
FDA Updates Two Digital Health Final Guidance Documents
FDA in Flux — January 2026 Newsletter

Share Article